When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
ACST - Acasti Pharma And Amarin In Severe Hypertriglyceridemia
Acasti Pharma Inc.
Branded Therapeutics: Vascepa
Therapeutically, Vascepa launched in 2013 by Amarin (AMRN) is the current market leader over Lovaza launched in 2005 by GlaxoSmithKline (GSK). Epanova from AstraZeneca (AZN) was approved by the FDA in 2014. However, prior to its launch in 2014, Amarin filed a lawsuit on patent infringement and the current status of the lawsuit remains unknown.
Vascepa was specifically approved to treat severe hypertriglyceridemia (>500 mg/dL) in patients, not on statin therapy (i.e. MARINE study). The ANCHOR trial showed that Vascepa was therapeutically effective in reducing high